Bisphosphonate-induced osteonecrosis of the jaw

Annals of Pharmacotherapy

Volumn 41, Issue 2, 2007, Pages 276-284

  Krueger, Courtney D ^a,b   West, Patricia M ^c   Sargent, Matthew ^b   Lodolce, Amy E ^a,b   Pickard, A Simon ^a,b  

^a Drug Information ^*  (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Bisphosphonates; Osteoporosis

Indexed keywords

ALENDRONIC ACID; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFLAMMATORY AGENT; BISPHOSPHONIC ACID DERIVATIVE; CEFTAZIDIME; CHLORHEXIDINE; CLINDAMYCIN; DEXAMETHASONE; ETIDRONIC ACID; FLUCONAZOLE; IBANDRONIC ACID; MELPHALAN; METRONIDAZOLE; PAMIDRONIC ACID; PENICILLIN G; PENICILLIN V POTASSIUM; PEROXIDE; PLACEBO; POTASSIUM IODIDE; RISEDRONIC ACID; THALIDOMIDE; TILUDRONIC ACID; ZOLEDRONIC ACID;

ADD ON THERAPY; BONE DENSITY; BONE MATRIX; BONE NECROSIS; BONE RESECTION; CANCER PATIENT; DEBRIDEMENT; DECORTICATION; DRUG ACCUMULATION; DRUG BINDING; DRUG INDUCED DISEASE; DRUG INHIBITION; DRUG RESPONSE; DRUG WITHDRAWAL; FEVER; FLU LIKE SYNDROME; HUMAN; HYPERBARIC OXYGEN; INFECTION COMPLICATION; INJECTION SITE REACTION; INJURY; JAW; KIDNEY DYSFUNCTION; MEDLINE; MOUTH HYGIENE; MOUTHWASH; MULTIPLE MYELOMA; PATIENT COUNSELING; PREVENTIVE DENTISTRY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEQUESTROTOMY; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW; TOOTH EXTRACTION; WOUND IRRIGATION;

ANTI-BACTERIAL AGENTS; DEBRIDEMENT; DIPHOSPHONATES; HUMANS; JAW DISEASES; MEDLINE; ORAL SURGICAL PROCEDURES; OSTEONECROSIS;

EID: 33847413194     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H521     Document Type: Review

References (59)

1. Novak KK, ed. Drug facts and comparisons. 60th ed. St. Louis, MO: Wolters Kluwer Health, 2006.
2. Hillner BE, Ingle JN, Chlebowski RT, et al.; American Society of Clinical Oncology. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-7.
3. Berenson JR, Hillner BE, Kyle RA, et al.; American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719-36.
4. Saad F. Bone-directed treatments for prostate cancer. Hematol Oncol Clin North Am 2006;20:947-63.
5. Package insert. Boniva (ibandronate injection). Research Triangle Park, NC: GlaxoSmithKline, January 2006.
6. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 2005;136:1658-68.
7. Liberman UA. Long-term safety of bisphosphonate therapy for osteoporosis: a review of the evidence. Drugs Aging 2006;23:289-98.
8. Pickett FA; American Academy of Oral Medicine. Bisphosphonate-associated osteonecrosis of the jaw: a literature review and clinical practice guidelines. J Dent Hyg 2006;80:10. Epub 1 Jul 2006.
9. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945-52.
10. Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006;81:1047-53.
11. Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61.
12. Treister N, Woo SB. Bisphosphonate-associated osteonecrosis of the jaw. N Engl J Med 2006;355:2348.
13. Soileau KM. Oral post-surgical complications following the administration of bisphosphonates given for osteopenia related to malignancy. J Periodontol 2006;77:738-43.
14. Tsai WS, Haghighi K, Placa SJ. Bisphosphonate-induced osteonecrosis of the jaws: a case report and literature review. Gen Dent 2006;54:215-9.
15. Leite AF, Figueiredo PT, Melo NS, et al. Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:14-21.
16. Mignogna MD, Fedele S, Lo Russo L, Ciccarelli R, Lo Muzio L. Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy. J Clin Oncol 2006;24:1475-7.
17. Errante D, Mannucci N, Bernardi D, Bianco A, Salvagno L. Comment on "Jaw avascular bone necrosis associated with long-term use of biphosphonates." Ann Oncol 2006;17:350-2.
18. Markiewicz MR, Margarone JE 3rd, Campbell JH, Aguirre A. Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge. J Am Dent Assoc 2005;136:1669-74.
19. Melo MD, Obeid G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc 2005;71:111-3.
20. Nelson MV. Special precautions (letter). Br Dent J 2005;198:628.
21. Olson KB, Hellie CM, Pienta KJ. Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid. Urology 2005;66:658.
22. Vannucchi AM, Ficarra G, Antonioli E, Bosi A. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol 2005;128:738.
23. Kademani D, Koka S, Lacy MQ, Rajkumar SV. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc 2006;81:1100-3.
24. Pastor-Zuazaga D, Garatea-Crelgo J, Martino-Gorbea R, Etayo-Perez A, Sebastian-Lopez C. Osteonecrosis of the jaws and bisphosphonates. Report of three cases. Med Oral Patol Oral Cir Bucal 2006;11:E76-9.
25. Dimitrakopoulos I, Magopoulos C, Karakasis D. Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. Int J Oral Maxillofac Surg 2006;35:588-93.
26. Dannemann C, Zwahlen R, Gratz KW. Clinical experiences with bisphosphonate-induced osteochemonecrosis of the jaws. Swiss Med Wkly 2006;136:504-9.
27. Salesi N, Pistilli R, Marcelli V, et al. Bisphosphonates and oral cavity avascular bone necrosis: a review of twelve cases. Anticancer Res 2006;26:3111-5.
28. Farrugia MC, Summerlin DJ, Krowiak E, et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 2006;116:115-20.
29. Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates-histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006;35:155-60.
30. Zarychanski R, Elphee E, Walton P, Johnston J. Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol 2006;81:73-5.
31. Thakkar SH, Isada C, Smith J, et al. Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias. Med Oncol 2006;23:51-6.
32. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust 2005;182:413-5.
33. Ficarra G, Beninati F, Rubino I, et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 2005;32:1123-8.
34. Katz H. Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws: a report of three cases. J Endod 2005;31:831-4.
35. Lenz JH, Steiner-Krammer B, Schmidt W, Fietkau R, Mueller PC, Gundlach KK. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates? J Craniomaxillofac Surg 2005;33:395-403.
36. Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. J Am Dent Assoc 2005;136:1675-81.
37. Merigo E, Manfredi M, Meleti M, et al. Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Biomed 2006;77:109-17.
38. Merigo E, Manfredi M, Meleti M, Corradi D, Vescovi P. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report. J Oral Pathol Med 2005;34:613-7.
39. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate- associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93.
40. Pires FR, Miranda A, Cardoso ES, et al. Oral avascular bone necrosis associated with chemotherapy and biphosphonate therapy. Oral Dis 2005;11:365-9.
41. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Aust 2005;182:417-8.
42. Sanna G, Zampino MG, Pelosi G, Nole F, Goldhirsch A. Jaw avascular bone necrosis associated with long-term use of bisphosphonates. Ann Oncol 2005;16:1207-8.
43. Bagan JV, Murillo J, Jimenez Y, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005;34:120-3.
44. Lugassy G, Shaham R, Nemets A, Ben-Dor D, Nahlieli O. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med 2004;117:440-1.
45. Carter GD, Goss AN. Bisphosphonates and avascular necrosis of the jaws (letter). Aust Dent J 2003;48:268.
46. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7.
47. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21:4253-4.
48. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003;61:1104-7.
49. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75.
50. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
51. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2006;23:8580-7.
52. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006;91:968-71.
53. Guarino MJ, Hill CE, Patel K. Bisphosphonates, cancer, and osteonecrosis-a single practice experience. Del Med J 2005;77:181-7.
54. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates (letter). N Engl J Med 2005;353:100-1.
55. Tosi P, Zamagni E, Cangini D, et al. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone (letter). Blood 2006;108:3951-2.
56. Hoff AO, Toth BB, Altundag K, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy (abstract 8528). J Clin Oncol 2006;24
57. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates (letter). N Engl J Med 2005;353:99.
58. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (biphossy jaw): is this the phossy jaw of the 21st century? J Oral Maxillofac Surg 2005;63:682-9.
59. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99.